SEARCH

SEARCH BY CITATION

Keywords:

  • BRAF inhibitor;
  • squamous cell carcinoma;
  • melanoma;
  • vemurafenib;
  • dabrafenib;
  • secondary malignancy

Summary

Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.